Petros Pharmaceuticals

Entity > Corporation > US > New York City New York > Petros Pharmaceuticals

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc. is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring and commercializing innovative therapeutics for men's health issues, including erectile dysfunction, Peyronie's disease, hormone health and substance use disorders.

Petros Pharmaceuticals, Inc. Launches Two Self-Selection Studies For Erectile Dysfunction Drug Stendra® (Avanafil): Results from these studies will be part of a broader data package the company plans to submit to the U.S. Food and Drug Administration (FDA) to potentially obtain over-the-counterdrug status for STENDRA® (avanafil).

Petros Pharmaceuticals Is Expanding Its Program For A Novel, Non-Invasive Treatment For Peyronie's Disease: In an effort to expand its portfolio to other underserved segments, Petros Pharmaceuticals recently entered into a definitive global exclusive license agreement for a novel and patented topical formulation candidate for the treatment of Peyronie's disease (PD), which is currently in early clinical testing. If approved, this would be the first and only clinically proven topical, non-invasive treatment for acute PD, a breakthrough achievement in men's health.

Petros Pharmaceuticals' Foundation: Petros Pharmaceuticals, formerly known as Metuchen Pharma, was founded in 2020 and is headquartered in the United States.

Petros Pharmaceuticals' Vision: Petros Pharmaceuticals' vision is to provide optimised men's health solutions that address the full spectrum of conditions that are specific to men, whether they focus on the male anatomy or pose an increased risk to men.

Industry: Business & Industrial > Pharmaceuticals & Biotech

More information about Petros Pharmaceuticals

Company Attribute Value
Address StreetAddress: 1185 Avenue of the Americas Fl 3, AddressLocality: New York City, AddressRegion: New York, PostalCode: 10036, AddressCountry: United States
Founding Date 2020
Name Petros Pharmaceuticals
Number Of Employees 24
Revenue $6,201,000 USD
Ticker Symbol NASDAQ: PTPI
Url petrospharma
Google google

Petros Pharmaceuticals


New York City, US
24 Sep 2023

New York City, US
24 Sep 2023

Petros Pharmaceuticals

Page: 1 Desktop | Laptop Devices
Petros Pharma
We ultimately seek to establish new foundations to Men's Health that can support vital functions of a man's life. Our focus. At Petros, we seek to understand ...
Rich Sitelinks
Rich Sitelinks
Petros Pharmaceuticals (@PetrosPharma) · Twitter › quote › PTPI
Petros Pharmaceuticals, Inc. (PTPI) Stock Price, News, ...
Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a leading provider of therapeutics for men's health, today announces the expansion of the FDA labeling for its oral ... › company › petros-pharmace...
Petros Pharmaceuticals
We collaborate with researchers, scientists, medical thought leaders and payers to ensure our therapies aid in restoring men's body function to vitality. › investing › stock › ptpi
PTPI - Petros Pharmaceuticals Inc. Stock Quote (U.S.
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, ... › PTPI › corporate_overview
Corporate Overview | Petros
Petros is a Men's Health pharmaceutical company that aims to develop complementary therapeutics designed for a man's journey, often, we believe, centered ... › news › petros-pharmaceut...
Petros Pharmaceuticals Announces Capital Raise of $15 ...
Jul 13, 2023 — Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or "the Company"), a pioneer in expanding consumer access to medication through the ... › Archives › edgar › data
Petros Pharmaceuticals Announces $10 Million Offering
The company will sell 2,153,333 shares in a registered direct offering and the remaining 1,180,000 shares will be sold in a private placement. Petros ... › organization › petros-p...
Petros Pharmaceuticals - Crunchbase Company Profile & ...
Petros Pharmaceuticals is a men's health pharmaceutical company that focuses on identifying, developing, acquiring, and commercializing novel therapeutics ...
Related Searches
Related Searches
petros pharmaceuticals news
Petros pharmaceuticals stock
petros pharmaceuticals stock prediction
Knowledge Panel
Knowledge Panel

Petros Pharma (Pharmaceutical company)

Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a leading provider of therapeutics for men's health, today announces the expansion of the FDA labeling for its oral erectile dysfunction (ED) drug, STENDRA® (avanafil), marketed by its subsidiary, Metuchen Pharmaceuticals.,Petros%20Pharmaceuticals%2C%20Inc.,by%20its%20subsidiary%2C%20Metuchen%20Pharmaceuticals.
  • Stock price : PTPI (NASDAQ) $1.51 -0.08 (-5.03%)Sep 22, 4:00 PM EDT - Disclaimer
  • Headquarters : United States
  • Founded : 2020

All information on this page is taken from publicly available sources, and the analysis we provide is a representation of Google's search results for the entity and does not represent any opinion or judgement about the entity by Kalicube itself. If you disagree with this analysis, please contact us and cite this reference : 193781